Table 2.
Univariate Analysis of Prognostic Factors for the Whole Cohort
| End Points | HR (95% CI) | P⁎ | End Points | HR (95% CI) | P⁎ |
|---|---|---|---|---|---|
| OS | LRFS | ||||
| Age, ≤50 years vs >50 years | 2.72 (1.48-4.97) | .001 | Age, ≤50 years vs >50 years | 1.16 (0.59-2.28) | .671 |
| Sex, men vs women | 0.31 (0.11-0.86) | .025 | Sex, men vs women | 1.48 (0.76-2.86) | .248 |
| Histology, WHO II vs WHO III | 1.21 (0.29-5.02) | .794 | Histology, WHO II vs WHO III | 1.05 (0.25-4.35) | .947 |
| History of smoking, no vs yes | 2.17 (1.18-3.99) | .012 | History of smoking, no vs yes | 0.76 (0.39-1.50) | .427 |
| T stage, T1-2 vs T3-4 | 2.14 (0.95-4.82) | .066 | T stage, T1-2 vs T3-4 | 1.28 (0.63-2.63) | .493 |
| N stage, N0-1 vs N2-3 | 1.97(0.99-3.92) | .054 | N stage, N0-1 vs N2-3 | 0.96 (0.40-2.28) | .925 |
| Clinical stage, II-III vs IVA-B | 2.79 (1.50-5.17) | .001 | Clinical stage, II-III vs IVA-B | 1.05 (0.48-2.28) | .897 |
| Primary dose, ≤68 vs >68 Gy | 0.79 (0.43-1.47) | .455 | Primary dose, ≤68 vs >68 Gy | 0.82 (0.44-1.53) | .526 |
| Cervical dose, ≤66 vs >66 Gy | 1.80 (0.94-3.45) | .078 | Cervical dose, ≤66 vs >66 Gy | 1.13 (0.57-2.22) | .727 |
| Treatment, CCRT vs NACT + CCRT | 1.24 (0.67-2.31) | .979 | Treatment, CCRT vs NACT + CCRT | 1.13 (0.59-2.14) | .715 |
| DMFS | PFS | ||||
| Age, ≤50 years vs >50 years | 1.37 (0.61-3.05) | .443 | Age, ≤50 years vs > 50years | 1.68 (1.04-2.72) | .033 |
| Sex, men vs women | 0.51 (0.18-1.48) | .215 | Sex, men vs women | 0.82 (0.46-1.44) | .482 |
| Histology, WHO II vs WHO III | 0.70 (0.17-2.95) | .625 | Histology, WHO II vs WHO III | 0.91 (0.33,2.50) | .858 |
| History of smoking, no vs yes | 1.05 (0.48-2.29) | .904 | History of smoking, no vs yes | 1.38 (0.86-2.20) | .179 |
| T stage, T1-2 vs T3-4 | 1.21 (0.51-2.87) | .658 | T stage, T1-2 vs T3-4 | 1.48 (0.85-2.58) | .170 |
| N stage, N0-1 vs N2-3 | 2.29 (1.00-5.24) | .049 | N stage, N0-1 vs N2-3 | 1.59 (0.91-2.77) | .105 |
| Clinical stage, II-III vs IVA-B | 2.51 (1.15-5.49) | .021 | Clinical stage, II-III vs IVA-B | 1.76 (1.06-2.94) | .029 |
| Primary dose, ≤68 vs >68 Gy | 1.18 (0.55-2.51) | .668 | Primary dose, ≤68 vs >68 Gy | 0.83 (0.51-1.32) | .426 |
| Cervical dose, ≤66 vs >66 Gy | 2.09 (0.95-4.60) | .068 | Cervical dose, ≤66 vs >66 Gy | 1.40 (0.84-2.32) | .194 |
| Treatment, CCRT vs NACT + CCRT | 0.78 (0.34-1.78) | .555 | Treatment, CCRT vs NACT + CCRT | 1.21 (0.75-1.95) | .428 |
Values in bold are significant (P < .05).
⁎
P values were calculated with an adjusted Cox proportional-hazards model.